NCT06349967View on ClinicalTrials.gov

Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

May 30, 2027

Conditions
Gastric Cancer
Interventions
DRUG

Nab-paclitaxel Combined With Cadonilimab (AK104)

Nab-paclitaxel 100mg/m2 ivgtt d1, d8, d15, q28d; Cadonilimab (AK104) 6mg/kg ivgtt d1, d15, q28d;

All Listed Sponsors
lead

West China Hospital

OTHER

NCT06349967 - Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter